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Abstract 
Remodeling or deregulation of the calcium signaling pathway is a relevant hallmark of cancer 
including cutaneous melanoma (CM). In the present study, using data from a published 
genome-wide association study (GWAS) from The University of Texas M.D. Anderson 
Cancer Center, we assessed the role of 41,377 common single nucleotide polymorphisms 
(SNPs) of 167 calcium signaling pathway genes in CM survival. We used another GWAS 
from Harvard University as the validation dataset. In the single-locus analysis, 1,830 SNPs 
were found to be significantly associated with CM-specific survival (CMSS) (P ≤ 0.050 and 
false-positive report probability ≤ 0.2), of which nine SNPs were validated in the Harvard 
study (P ≤ 0.050). Among these, three independent SNPs (i.e., PDE1A rs6750552 T>C, 
ITPR1 rs6785564 A>G and RYR3 rs2596191 C>A) had a predictive role in CMSS, with a 
meta-analysis derived hazards ratio (HR) of 1.52 [95% confidence interval (CI) = 1.19-1.94, P 
= 7.21×10-4]], 0.49 (0.33-0.73, 3.94×10-4) and 0.67 (0.53-0.86, 0.0017), respectively. Patients 
with an increasing number of protective genotypes had remarkably improved CMSS. 
Additional expression quantitative trait loci (eQTL) analysis showed that these genotypes 
were also significantly associated with mRNA expression levels of the genes. Taken together, 
these results may help us to identify prospective biomarkers in the calcium signaling pathway 
for CM prognosis. 
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Summary 
We used genotypes from two genome-wide association studies in a two-stage analysis and 
found that three SNPs in PDE1A, ITPR1 and RYR3 modulated the survival of cutaneous 
melanoma patients, suggesting that these genetic variants may be promising predictors of 
cutaneous melanoma. 
Abbreviations: 
CM cutaneous melanoma 
SNP single-nucleotide polymorphisms 
GWAS genome-wide association studies 
MDACC  The University of Texas MD Anderson Cancer Center 
CMSS cutaneous melanoma-specific survival 
HR hazards ratio 
CI confidence interval 
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eQTL expression quantitative trait loci 
FPRP false-positive report probability 
ROC receiver operating characteristic 
AUC area under the curve 
PDE1A phosphodiesterase 1A 
ITPR1 inositol 1,4,5-trisphosphate receptor type 1 
RYR3 ryanodine receptor 3 
Keywords: cutaneous melanoma, calcium signaling pathway, single-nucleotide 
polymorphism, genome-wide association study, melanoma-specific survival 
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Introduction 
Cutaneous melanoma (CM) remains a clinical challenge for management worldwide. In 2018, 
an estimated 91,270 adults will be diagnosed with CM, and 9,320 patients will die from this 
disease in the United States (1). As the most unfavorable and lethal skin cancer, the 
distant-stage CM generally has a poor prognosis with a five-year survival of about 20% (2). 
Thus, it is imperative to understand molecular mechanisms underlying the prognosis of CM. 
It is broadly accepted that calcium is ubiquitously involved in nearly every aspect of 
cellular processes in humans, including cell growth, proliferation and even cell death (3,4), 
and thus the molecule has been appropriately referred to as the life and death signal (5). In 
2000, Hanahan and Weinberg proposed six hallmark capabilities of cancer (6), calcium 
signaling is connected either directly or indirectly to each of these processes; therefore, it has 
been proposed that cancer is a perversion of some normal calcium-related processes and 
that calcium is the central control of carcinogenesis (7), in which the calcium influx across 
different cellular compartments is a key trigger or a regulator of the process (8). In the past 
decades, a growing number of studies have shown that components of the calcium signaling 
pathway are remodeled or deregulated in cancer (9,10). For example, as one of transient 
receptor potential (TRP) channels, TRPM8 was found to be associated with various types of 
cancer, such as melanoma and cancers of the pancreas, breasts, colorectum and lung 
(11-13). 
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Cancers differ in the types of calcium channels and pumps that were initially recruited, 
and several studies have explored the role of the calcium signaling in CM development and 
progression. For example, Maiques et al. found a significant increase in expression of the 
T-type channel isoform Cav3.1 in primary and malignant melanoma, compared with normal
skin and nevi, and the expression levels of another isoform Cav3.2 were significantly higher 
in metastatic melanoma than in primary melanoma (14); furthermore, the store-operated Ca2+ 
entry (SOCE) was found to contribute to melanoma progression and cell migration (15). 
However, the role of the calcium signaling pathway in the prognosis of melanoma remains 
unknown. 
Genome-wide association study (GWAS) provides a broad approach to identify genes 
involved in carcinogenesis and tumor progression. An increasing number of genetic variants, 
such as single-nucleotide polymorphisms (SNPs), have been found to be associated with CM 
risk or survival (16), in which the two-step gene-set or pathway analysis has been applied to 
understanding of the effects of genes and their biological pathways on CM development and 
progression (17). In the present study, we performed a gene-set-based pathway analysis of 
two existing CM GWAS datasets to assess the associations between genetic variants in the 
calcium signaling pathway genes and CM-specific survival (CMSS). 
Materials and methods 
Discovery dataset 
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We used a published GWAS study from The University of Texas MD Anderson Cancer 
Center (MDACC) as the discovery dataset (18), in which 858 cases who had both complete 
questionnaire data and detailed clinical information were included in the final analysis. 
Genotyping data were obtained from the existing GWAS genotyping data generated by 
Illumina HumanOmni-Quad_v1_0_B array and made available at the National Center for 
Biotechnology Information (NCBI) Database of Genotypes and Phenotypes (dbGaP Study 
Accession: phs000187.v1.p1) (19,20), in which the genome-wide imputation was performed 
by the MACH software based on the 1000 Genomes project phase I v2 CEU (Northern 
Europeans from Utah) (March 2010 release) (21). 
Validation dataset 
The significant SNPs obtained from the discovery dataset were further validated by using the 
Harvard GWAS study that was previously described elsewhere (22), in which 409 
non-Hispanic white subjects with survival data were included in the final analysis. The 
Harvard GWAS genotyping was performed with Illumina HumanHap610 array, and the 
genome-wide imputation was also performed using the MACH software based on the 1000 
Genomes Project CEU (Northern Europeans from Utah) data (phase I v3, March 2012) (23). 
All subjects provided a written informed consent at both MDACC and Brigham and 
Women’s Hospital that had been approved by the local Institutional Review Boards. 
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Gene and SNP extraction 
The gene-set pathway to be analyzed, 178 genes were selected from the category of ‘calcium 
signaling pathway’ in the Molecular Signatures Database (http://software.broadinstitute.org/ 
gsea/msigdb/index.jsp). Because there are no standard statistics established for the 
sex-specific analysis as females carry two copies of chromosome X and males are 
hemizygous for this chromosome, 10 genes on X chromosome as well as one pseudogene 
were excluded, the remaining 167 genes located on autosomes were used as the candidate 
genes (Supplementary Table S1). We then mapped all the SNPs located within 2-kb up- 
and down-streams of those selected genes and extracted their summary SNP data from the 
MDACC GWAS dataset. The quality control of the genotyping data included minor allele 
frequency (MAF) ≥ 0.05, genotyping rate ≥ 95%, and Hardy-Weinberg equilibrium (HWE) P 
value ≥ 1×10-5. 
Statistical analysis 
CMSS was calculated from the date of diagnosis with CM to the CM-related death or the date 
of the last follow-up. Adjusted hazards ratios (HRs) from the multivariate Cox proportional 
hazards regression models were conducted using an additive genetic model for both MDACC 
and Harvard GWAS datasets with the GenABEL package of R software (version 3.3.3). As a 
result of the imputation that provided the majority of SNPs to be analyzed, there was a high 
level of correlations among SNPs used in the final analysis, for which the false-positive report 
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probability (FPRP) method was preferably chosen for the multiple testing correction (24), we 
assigned a prior probability of 0.10 to detect an HR of 2.0 for an association with variant 
genotypes or minor alleles of the SNPs with P ≤ 0.05. Only SNPs with an FPRP value ≤ 0.2 
were chosen for validation in the Harvard GWAS dataset. 
Meta-analysis of SNPs from both discovery and validation datasets was also performed 
using a fixed-effects model. If the Cochran’s Q test P-value ≤ 0.100 or the heterogeneity 
statistic (I2) ≥ 25%, a random-effects model was employed. Validated SNPs and clinical 
variables were then put into the multivariable stepwise Cox model to select the independent 
SNPs, with both the entry and stay points for the models set to 0.05. We summarized the 
number of genetic variants to evaluate the combined effect of all independent or 
representative SNPs on CMSS. Receiver operating characteristic (ROC) curve was used to 
illustrate the ability of area under the curve (AUC) in predicting CMSS. A time-dependent 
ROC analysis was also performed with timeROC package of R software to assess the 
accuracy of genetic variants’ continuing effect over the time. 
We also performed in silico functional validation of the significant SNPs to further 
explore the molecular mechanisms underlying the observed CM-death associations with the 
genotypes. Specifically, we conducted expression quantitative trait loci (eQTL) analysis with 
data from the Cancer Genome Atlas (TCGA) database (dbGaP Study Accession: 
phs000178.v9.p8) (25). 
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All other analyses were performed with SAS (version 9.3.3; SAS Institute, Cary, NC, 
USA), if not specified otherwise. 
Results 
Patient characteristics 
The final analyses included 858 patients from the MDACC GWAS study and 409 patients 
from the Harvard GWAS study (Supplementary Table S2). Because MDACC patients were 
from a tertiary care center, the patient population tended to be enriched for late-stage and 
younger patients, compared with the patients from the general population that was captured 
by the Harvard cohort studies. The use of cases from a cohort also resulted in fewer clinical 
variables available in the Harvard GWAS Study. In the MDACC study, ages of the patients at 
diagnosis were between 17 and 94 years (52.4±14.4 years), with a percentage of 57.8% and 
42.2% for men and women, respectively, and patients with stages I/II (82.6%) were more 
than those with stages III/IV (17.4%) that were also defined as regional/distant metastasis. 
Univariate analysis showed that age, sex, regional/distant metastasis, Breslow thickness, 
ulceration, and mitotic rate were significantly associated with CMSS. In the Harvard study, 
however, only age, sex, survival outcome and genotype data were available for analysis; the 
ages of eligible cases at diagnosis were between 34 to 87 years (61.1 ± 10.8 years), and 
82.4% of these patients were over 50 years old; there were more women than men, with a 
percentage of 66.3% and 33.7%, respectively; and only age was significantly associated with 
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CMSS in the univariate analysis. In comparison with patients from the MDACC study that had 
a median follow-up time of 81.1 months, patients from the Harvard study had a relatively 
longer median follow-up time (179.0 months), but the death rates during the follow-up period 
were similar between the MDACC (95/858, 11.1%) and the Harvard studies (48/409, 11.5%). 
Associations between SNPs in the calcium signaling pathway genes and CMSS 
We extracted 41,377 SNPs (6,606 genotyped and 34,771 imputed) in the relevant genes with 
2-kb flanking regions from the MDACC GWAS dataset, and the study flowchart is presented
in Figure 1. The Manhattan plot of associations between these SNPs and CMSS is also 
presented in Supplementary Figure S1. In the single-locus analysis of the MDACC 
discovery dataset, 3,346 SNPs were found to be significantly associated with CMSS (P ≤ 
0.050), of which 1,830 SNPs were worthy of being further explored after the correction by an 
FPRP ≤ 0.2. The effects of these SNPs on CMSS were then validated in the Harvard GWAS 
dataset. As a result, nine SNPs in four genes remained significant, of which rs2623439, 
rs1430157, rs6750552 and rs10931014 in PDE1A were associated with a poorer survival, 
while rs485412, rs1104370 and rs2841038 in CHRM3, rs6785564 in ITPR1, and rs2596191 
in RYR3 were associated with a better survival. Meta-analysis of these nine SNPs from the 
two GWAS datasets confirmed the same associations (Table 1), and no significant 
heterogeneity was observed in the effects of these SNPs across the two datasets. Linkage 
Ac
ce
pte
d M
an
us
cri
pt
13 
disequilibrium (LD) plots showed that both the three SNPs in CHRM3 and the four SNPs in 
PDE1A were in LD (Supplementary Figure S2). 
Genetic variants in the calcium signaling pathway genes as independent survival predictors 
To identify independent genetic predictors of CMSS, the nine validated SNPs together with 
selected clinical variables from the MDACC study were all included in a multivariable 
stepwise Cox regression model. As a result, age, metastasis, Breslow thickness, ulceration, 
mitotic rate, and three SNPs (i.e., PDE1A rs6750552, ITPR1 rs6785564 and RYR3 
rs2596191), but not sex, were significantly and independently associated with CMSS (Table 
2). Therefore, we selected these three SNPs as independent and representative SNPs for 
further analyses. 
As shown in Table 3, in the MDACC study, the risk effect of PDE1A rs6750552 C allele as 
well as protective effects of ITPR1 rs6785564 G and RYR3 rs2596191 A alleles on CM 
survival were statistically significant (trend test: P = 0.013, 0.004, and 0.016, respectively), 
and similar results were observed in the Harvard study (trend test: P = 0.022, 0.040, and 
0.039, respectively). When we combined MDACC and Harvard datasets into one dataset 
(n=1267), consistent results were observed (trend test: P = 0.007, 0.019, and 0.003, 
respectively). For illustrative purposes, each SNP in its gene with 20 kilobases flanking region 
is shown in a regional association plot (Supplementary Figure S3). 
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Combined analyses of the three independent and representative SNPs 
To better interpret the joint effect of the three independent and representative SNPs on risk of 
death, we combined protective genotypes of rs6750552 TT, rs6785564 AG+GG and 
rs2596191 CA+AA into one variable of the number of protective genotypes as a genetic 
score. As shown in Table 3, the trend test demonstrated that an increased genetic score was 
associated with an improved survival in the MDACC study (P < 0.001), the Harvard study (P = 
0.0002) and the combined dataset (P < 0.0001). Compared with those who had no protective 
genotypes, patients with three protective genotypes had the best survival (MDACC: HR = 
0.15, 95% CI = 0.05-0.52, and P = 0.003; Harvard: HR = 0.13, 95% CI = 0.03-0.56, and P = 
0.0063; the combined dataset: HR = 0.23, 95% CI = 0.10-0.52, and P = 0.0004). Next, we 
dichotomized all patients into a group with 0-1 protective genotypes and a group with 2-3 
protective genotypes, and, compared with the former group, the latter group had a 
significantly better survival (MDACC: HR = 0.49, 95% CI = 0.31-0.76, and P = 0.002; Harvard: 
HR = 0.48, 95% CI = 0.26-0.90, and P = 0.021; combined dataset: HR = 0.61, 95% CI = 
0.43-0.86, and P = 0.0049). Finally, we used Kaplan-Meier curves to visualize associations 
between the number of protective genotypes and CMSS (Figure 2a-f). 
Stratified analyses for the combined protective genotypes on CMSS 
We further conducted stratified analyses to assess whether the combined effect of protective 
genotypes on CMSS was modified by clinicopathologic variables. In the MDACC study, 
Ac
ce
pte
d M
an
us
cri
pt
15 
patients with 2-3 protective genotypes, compared with those with 0-1 protective genotypes, 
had a significantly reduced risk of CM death in the subgroups of age > 50 years, male, 
patients with regional/distant metastasis, and patients with Breslow thickness > 1 mm. The 
difference was also obvious between subgroups of patients with and without ulceration and 
mitotic rate ≤1mm2 and >1 mm2. In the Harvard study, although only age and sex were 
available for the analysis, a similar trend was observed in the subgroup of age > 50 years. 
However, no heterogeneity was observed among all the subgroups of the two studies 
(Supplementary Table S3). 
In silico functional validation 
The eQTL analysis with data from the TCGA database was performed in two groups: primary 
and metastatic CM tissues. As genotyping data for PDE1A rs6750552 were not available in 
the TCGA database, we chose PDE1A rs2368253 that is in a high LD with rs6750552 
(r2=0.84) as an alternative SNP. As shown in Figure 3a-c, the minor rs2368253 C allele had 
a significant correlation with an increased mRNA expression level of PDE1A in metastatic CM 
tissue (P value was 0.006, 0.042 and 0.010 in additive, dominant and recessive models, 
respectively), but no significant difference was observed in primary CM tissue 
(Supplementary Figure S4a-c). We also found a significant correlation between the minor 
ITPR1 rs6785564 G allele and a decreased mRNA expression level of ITPR1 in primary CM 
tumor tissue in a dominant model (P = 0.042; Figure 3e), but not in other models nor in 
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metastatic CM tissue (Figure 3d, 3f; Supplementary Figure S4d-f). A significant correlation 
between the minor RYR3 rs2596191 A allele and a decreased mRNA expression level of 
RYR3 was also noticed in metastatic CM tissue in both additive and dominant models (P = 
0.041 and 0.029, respectively; Figure 3g, 3h), but not in primary CM tissue (Supplementary 
Figure S4g-i). These results suggest that PDE1A rs6750552 C, ITPR1 rs6785564 G and 
RYR3 rs2596191 A alleles have an independent effect on their gene expression at the 
transcription level, which are consistent with their effects on survival of CM patients. 
We furthermore explored potential functions of these SNPs by using data from the 
ENCODE Project. PDE1A rs6750552 SNP is located in a DNase I hypersensitive site, and 
RYR3 rs2596191 SNP is located at the intron region with considerable levels of the 
H3K4Me1 enrichment, but nothing was found for ITPR1 rs6785564; however, ITPR1 
rs7642352, which is in a high LD with rs6785564 (r2=0.87), is located in a DNase I 
hypersensitive site with considerable levels of the H3K4Me1 enrichment (Supplementary 
Figure S5a-c). 
The ROC curve and time dependent AUC for CMSS prediction 
We further assessed prediction effect of the genotypes of PDE1A rs6750552 C, ITPR1 
rs6785564 G and RYR3 rs2596191 A in the same model with age and sex by using the ROC 
curve and time-dependent AUC in the combined MDACC and Harvard dataset. From the 
ROC curve, we observed a significantly improvement for these protective genotypes in 
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combination with age and sex in prediction performance of the 5-year CMSS, compared with 
the model with age and sex only (AUC = 61.25% to 67.21%, P = 5.79×10-4), and the 
time-dependent AUC curve showed this significant effect continuously through the entire 
follow-up period (Figure 2g-h). 
Discussion 
In recent years, it has been recognized that the alternations in the calcium signaling are 
involved in carcinogenesis and tumor progression. The core components of the calcium 
signaling system are referred as the “calcium toolkit” (10), and remodeling or deregulation of 
the calcium signaling pathway, as a cause or consequence of different cancer-related 
proteins with altered functions, is particularly relevant to the hallmarks of cancer cells (26). 
Therefore, the key calcium signaling molecules are likely to be promising biomarkers for 
cancer development and prognosis, even a novel and prospective target for cancer treatment 
(27,28). However, few studies have investigated the roles of genetic variants in calcium 
signaling pathway genes in predicting the survival of CM patients. In the present study of 167 
genes involved in the calcium signaling pathway, we showed that PDE1A rs6750552, ITPR1 
rs6785564 and RYR3 rs2596191 were independently or jointly associated the survival of CM 
patients, suggesting that these genetic variants may be promising prognostic predictors of 
CM. Therefore, the present study highlights the possible role of the calcium signaling
pathway in CM progression. 
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PDE1A, located on chromosome 2q32.1, encodes a member of Ca2+/ 
calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1), which is one of the key 
enzymes involved in the complex interactions between the cyclic nucleotide and Ca2+ second 
messenger systems (29,30). Although associations between the PDE genes and genetic 
diseases have been investigated for several years, specific members of the PDE family have 
recently been implicated in carcinogenesis and tumor progression (31,32). For example, one 
study found a high PDE1A mRNA expression in several malignant tumor cells, including 
human oral melanoma cell lines (33). Another study showed that inhibition of selective PDE 
isoforms induced apoptosis and cell cycle arrest of tumor cells and regulated the tumor 
microenvironment (34). In the present study, the rs6750552 C variant genotypes were found 
to be associated with a decreased CMSS. From the eQTL analyses results of another SNP 
rs2368253 in a high LD with rs6750552, we inferred that the variant C genotypes were also 
associated with an increased PDE1A mRNA expression level in metastatic CM tissue. In 
addition, according to the ENCODE Project data, the rs6750552 SNP is located in a DNase I 
hypersensitive site; therefore, it is likely that this SNP could affect PDE1A expression by 
modifying the accessibility of chromatin during transcription, further influencing the gene 
function. More recently, curcumin, a new candidate for melanoma therapy, has been reported 
to play an anti-proliferative effect on melanoma cells by inhibiting PDE1A, and it was also 
reported that PDE1A expression was positively correlated with UHRF1 (ubiquitin-like 
containing PHD and Ring Finger domains 1) expression, which may be a key factor in DNA 
methylation and histone modification implicated in cell cycle progression (35). Meanwhile, 
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another recent study demonstrated that the elevated expression of UHRF1 played an 
important role in melanoma cell proliferation and progression, clinically related to high TNM 
classification and Breslow's thickness, and that high UHRF1 was positively associated with a 
shorter overall survival of melanoma patients (36). These may partly explain the potential 
biology and molecular mechanism of PDE1A underlying the observed association. 
ITPR1, located on chromosome 3p26.1, encodes an intracellular receptor for inositol 
1,4,5-trisphosphate that is a ligand-gated calcium channel, which modulates intracellular 
calcium signaling following stimulation by inositol 1,4,5-trisphosphate and mediates calcium 
release from the endoplasmic reticulum (37). Results from Riker Melanoma in the cancer 
microarray database (Oncomine) showed a higher expression level of ITPR1 in CM tissue 
than in normal skin tissues (38), suggesting an oncogenic role of the gene. Recent evidence 
shows that ITPRs play a crucial role in the regulation of autophagy (39,40), which is involved 
in regulating the NK-mediated immune response in many tumor cells; for example, ITPR1 
was recognized as an autophagy sensor, the overexpression of ITPR1 impaired NK 
cell-mediated anti-tumor immune response in clear renal cell carcinoma (41). These results 
suggest that inhibiting ITPR1/autophagy in tumors may improve their elimination by NK cells 
in vivo. In the present study, the rs6785564 G allele was consistently found to be associated 
with a decreased mRNA expression level of ITPR1 in primary CM tissue and a better survival 
of CM patients. Also from the ENCODE Project data, rs7642352 that is in a high LD with 
rs6785564 is located in a DNase I hypersensitive site with H3K4Me1 enrichment; thus, SNPs 
in this gene region probably influence the gene function, likely by mediating gene expression 
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at the mRNA transcription level. Taken together, these may explain the possible mechanisms 
underlying the association between ITPR1 rs6785564 and CMSS. 
RYR3, located on chromosome 15q13.3-q14, encodes the third isoform of the ryanodine 
receptor (RYR) family. RYR3 is a Ca2+-induced Ca2+ release (CICR) channel protein located 
in the sarcoplasmic reticulum, and it plays a key role in controlling cytosolic calcium levels. 
Previous studies demonstrated that a genetic variant, rs1044129 A→G, which was present in 
the microRNA-367 binding site in the 3′UTR of RYR3, had an effect on breast cancer 
progression-free survival, and it was also reported to be relevant to relapse-free survival in 
Korean patients with resected colonic cancer and postoperative survival in Chinese patients 
with hepatocellular carcinoma (42-44). In the present study, patients with the rs2596191 A 
allele had a better survival, and eQTL analyses of this genotype showed a correlation with a 
decreased mRNA expression level of RYR3. Additionally, the rs2596191 SNP is located at 
the intron region with considerable levels of the H3K4Me1 enrichment, according to the 
ENCODE Project data, which is likely associated with enhancers and transcription starts, and 
thus SNPs in this region may act as enhancers to affect gene expression by modifying the 
transcriptional activities. Unfortunately, there is lack of studies of the molecular mechanisms 
underlying altered RYR3 mRNA expression on CMSS, therefore, further functional 
investigation is needed. 
Limitations of the present study should be noticed. First, clinical variables of the 
discovery and validation datasets were not matched, only age and sex were available from 
the Harvard cohort studies; however, no heterogeneity was observed in their comparisons or 
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combined analysis. Second, some valuable clinical information, such as performance status 
and treatment, were also absent in both studies; thus, we were restricted from an extended 
CM survival analysis. Third, the exact biological mechanisms about how those variants affect 
DNA methylation or mRNA expression remains unclear. Therefore, the results of the present 
study should be considered preliminary, and it is necessary to replicate the results in studies 
with other larger and independent populations with different races or geographic regions, in 
which functional experiments should also be conducted for further exploration. Once 
validated, these genetic variants may help us to identify key calcium toolkit molecules that 
may lead to the development of novel and prospective biomarkers for CM prognosis. 
Supplementary material 
Supplementary data are available at Carcinogenesis online. 
Funding 
The MD Anderson Study was supported by National Institutes of Health/National Cancer 
Institute (R01 CA100264, 2P50CA093459 and R01CA133996) as well as by The University 
of Texas MD Anderson Cancer Center Various Donors Melanoma and Skin Cancers Priority 
Program Fund; the Miriam and Jim Mulva Research Fund; the McCarthy Skin Cancer 
Research Fund and the Marit Peterson Fund for Melanoma Research. The Harvard Study 
was in part supported by National Institutes of Health/National Cancer Institute (R01 
Ac
ce
pte
d M
an
us
cri
pt
22 
CA49449, P01 CA87969, UM1 CA186107 and UM1 CA167552). Qingyi Wei was supported 
by the start-up funds from Duke Cancer Institute, Duke University Medical Center, and also in 
part supported by the Duke Cancer Institute as part of the P30 Cancer Center Support Grant 
(Grant ID: NIH CA014236). Xiaomeng Wang was supported by the Scholarship from The 
First Hospital of Jilin University, Changchun, China. 
Acknowledgements 
We thank all of the investigators and funding agencies that enabled the deposition of data in 
dbGaP that we used in the present study. We also thank the John Hopkins University Center 
for Inherited Disease Research for conducting high-throughput genotyping for this study. We 
thank all the participants and staff of the Nurses’ Health Study (NHS) and Health 
Professionals Follow-up Study (HPFS) for their valuable contributions. The results published 
here are in whole or part based upon data generated by The Cancer Genome Atlas pilot 
project established by the NCI and NHGRI. The authors assume full responsibility for 
analyses and interpretation of these data. 
Conflict of Interest Statement 
None declared. 
Ac
ce
pte
d M
an
us
cri
pt
23 
References 
1. Siegel, R.L., et al. (2018) Cancer statistics, 2018. CA Cancer J Clin, 68, 7-30.
2. American Cancer Society, A. (2018) Cancer Facts & Figures 2018. ACS website.
cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-canc
er-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf.
3. Clapham, D.E. (2007) Calcium signaling. Cell, 131, 1047-58.
4. Humeau, J., et al. (2017) Calcium signaling and cell cycle: progression or death. Cell
Calcium.
5. Berridge, M.J., et al. (1998) Calcium--a life and death signal. Nature, 395, 645-8.
6. Hanahan, D., et al. (2000) The hallmarks of cancer. Cell, 100, 57-70.
7. Kadio, B., et al. (2016) Calcium role in human carcinogenesis: a comprehensive
analysis and critical review of literature. Cancer Metastasis Rev, 35, 391-411.
8. Monteith, G.R., et al. (2012) Calcium channels and pumps in cancer: changes and
consequences. J Biol Chem, 287, 31666-73.
9. Stewart, T.A., et al. (2015) Altered calcium signaling in cancer cells. Biochim Biophys
Acta, 1848, 2502-11.
10. Prevarskaya, N., et al. (2014) Remodelling of Ca2+ transport in cancer: how it
contributes to cancer hallmarks? Philos Trans R Soc Lond B Biol Sci, 369, 20130097.
11. Tsavaler, L., et al. (2001) Trp-p8, a novel prostate-specific gene, is up-regulated in
prostate cancer and other malignancies and shares high homology with transient
receptor potential calcium channel proteins. Cancer Res, 61, 3760-9.
12. Liu, Z., et al. (2016) TRPM8: a potential target for cancer treatment. J Cancer Res
Clin Oncol, 142, 1871-81.
Ac
ce
pte
d M
an
us
cri
pt
24 
13. Yee, N.S. (2015) Roles of TRPM8 Ion Channels in Cancer: Proliferation, Survival, and
Invasion. Cancers (Basel), 7, 2134-46.
14. Maiques, O., et al. (2017) Immunohistochemical analysis of T-type calcium channels
in acquired melanocytic naevi and melanoma. Br J Dermatol, 176, 1247-1258.
15. Umemura, M., et al. (2014) Store-operated Ca2+ entry (SOCE) regulates melanoma
proliferation and cell migration. PLoS One, 9, e89292.
16. Law, M.H., et al. (2015) Genome-wide meta-analysis identifies five new susceptibility
loci for cutaneous malignant melanoma. Nat Genet, 47, 987-995.
17. Yuan, H., et al. (2015) Genetic variants in Hippo pathway genes YAP1, TEAD1 and
TEAD4 are associated with melanoma-specific survival. Int J Cancer, 137, 638-45.
18. Amos, C.I., et al. (2011) Genome-wide association study identifies novel loci
predisposing to cutaneous melanoma. Hum Mol Genet, 20, 5012-23.
19. Mailman, M.D., et al. (2007) The NCBI dbGaP database of genotypes and
phenotypes. Nat Genet, 39, 1181-6.
20. Tryka, K.A., et al. (2014) NCBI's Database of Genotypes and Phenotypes: dbGaP.
Nucleic Acids Res, 42, D975-9.
21. Li, Y., et al. (2010) MaCH: using sequence and genotype data to estimate haplotypes
and unobserved genotypes. Genet Epidemiol, 34, 816-34.
22. Song, F., et al. (2012) Exonuclease 1 (EXO1) gene variation and melanoma risk. DNA
Repair, 11, 304-309.
23. Lappalainen, T., et al. (2013) Transcriptome and genome sequencing uncovers
functional variation in humans. Nature, 501, 506-11.
24. Wacholder, S., et al. (2004) Assessing the probability that a positive report is false: an
approach for molecular epidemiology studies. J Natl Cancer Inst, 96, 434-42.
Ac
ce
pte
d M
an
us
cri
pt
25 
25. Network, T.C.G.A. (2015) Genomic Classification of Cutaneous Melanoma. Cell, 161,
1681-1696.
26. Roderick, H.L., et al. (2008) Ca2+ signalling checkpoints in cancer: remodelling Ca2+
for cancer cell proliferation and survival. Nat Rev Cancer, 8, 361-75.
27. Cui, C., et al. (2017) Targeting calcium signaling in cancer therapy. Acta Pharm Sin B,
7, 3-17.
28. Prevarskaya, N., et al. (2013) Targeting Ca2+ transport in cancer: close reality or long
perspective? Expert Opinion on Therapeutic Targets, 17, 225-241.
29. Kakkar, R., et al. (1999) Calmodulin-dependent cyclic nucleotide phosphodiesterase
(PDE1). Cell Mol Life Sci, 55, 1164-86.
30. Michibata, H., et al. (2001) Human Ca2+/calmodulin-dependent phosphodiesterase
PDE1A: novel splice variants, their specific expression, genomic organization, and
chromosomal localization. Biochim Biophys Acta, 1517, 278-87.
31. Levy, I., et al. (2011) Phosphodiesterase function and endocrine cells: links to human
disease and roles in tumor development and treatment. Curr Opin Pharmacol, 11,
689-97.
32. Keravis, T., et al. (2012) Cyclic nucleotide phosphodiesterase (PDE) isozymes as
targets of the intracellular signalling network: benefits of PDE inhibitors in various
diseases and perspectives for future therapeutic developments. Br J Pharmacol, 165,
1288-305.
33. Shimizu, K., et al. (2005) Calmodulin-dependent phosphodiesterase (PDE) 1 in
human oral melanoma cell lines. International Journal of Oral and Maxillofacial
Surgery, 34, 4.
34. Savai, R., et al. (2010) Targeting cancer with phosphodiesterase inhibitors. Expert
Opin Investig Drugs, 19, 117-31.
Ac
ce
pte
d M
an
us
cri
pt
26 
35. Abusnina, A., et al. (2011) Anti-proliferative effect of curcumin on melanoma cells is
mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1.
Molecular Nutrition & Food Research, 55, 1677-1689.
36. Wei, C., et al. (2018) Upregulation of UHRF1 promotes the progression of melanoma
by inducing cell proliferation. Oncol Rep, 39, 2553-2562.
37. Foskett, J.K., et al. (2007) Inositol trisphosphate receptor Ca2+ release channels.
Physiol Rev, 87, 593-658.
38. Riker, A.I., et al. (2008) The gene expression profiles of primary and metastatic
melanoma yields a transition point of tumor progression and metastasis. BMC Med
Genomics, 1, 13.
39. Ivanova, H., et al. (2014) Inositol 1,4,5-trisphosphate receptor-isoform diversity in cell
death and survival. Biochim Biophys Acta, 1843, 2164-83.
40. Decuypere, J.P., et al. (2015) ITPRs/inositol 1,4,5-trisphosphate receptors in
autophagy: From enemy to ally. Autophagy, 11, 1944-8.
41. Messai, Y., et al. (2014) ITPR1 protects renal cancer cells against natural killer cells
by inducing autophagy. Cancer Res, 74, 6820-32.
42. Zhang, L., et al. (2011) Functional SNP in the microRNA-367 binding site in the 3'UTR
of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk
and calcification. Proc Natl Acad Sci U S A, 108, 13653-8.
43. Chae, Y.S., et al. (2013) Functional polymorphism in the MicroRNA-367 binding site
as a prognostic factor for colonic cancer. Anticancer Res, 33, 513-9.
44. Peng, C., et al. (2015) A polymorphism at the microRNA binding site in the 3'
untranslated region of RYR3 is associated with outcome in hepatocellular carcinoma.
Onco Targets Ther, 8, 2075-9.
Ac
ce
pte
d M
an
us
cri
pt
28 
Figure legends 
Figure 1. Study flowchart. (Abbreviations: MDACC: The University of Texas M.D. Anderson 
Cancer Center; CM: cutaneous melanoma; GWAS: genome-wide association study; SNP: 
single nucleotide polymorphism; FPRP: false-positive report probability; AUC: area under the 
curve; ROC: receiver operating characteristic.) 
Figure 2. The independent SNPs and cutaneous melanoma-specific survival (CMSS). 
(a-f) Kaplan-Meier survival curves of the protective genotypes: the exact numbers of 
protective genotypes in (a) in the MDACC study, (c) in the Harvard study, and (e) in 
combination of these two datasets; dichotomiazed groups of protective genotypes (b) in the 
MDACC study, (d) in the Harvard study, and (f) in the combined dataset. (g-h) Receiver 
operating characteristic (ROC) curve and time-dependent area under the curve (AUC) 
estimation for prediction of melanoma-specific survival in the combined dataset. (g). 
Five-year melanoma-specific survival prediction by ROC curve; (h). Time-dependent AUC 
estimation: based on age, sex and the protective genotypes of the three genes. 
Figure 3. The expression quantitative trait loci (eQTLs) analysis from The Cancer 
Genome Atlas (TCGA) database. Correlation between PDE1A mRNA expression and 
rs2368253 genotypes in metastatic cutaneous melanoma tumor tissue in the (a) additive 
model, (b) dominant model, (c) recessive model. Correlation between ITPR1 mRNA 
Ac
ce
pte
d M
an
us
cri
pt
29 
expression and rs6785564 genotype in primary cutaneous melanoma tumor tissue in the (d) 
additive model, (e) dominant model, and (f) recessive model. Correlation between RYR3 
mRNA expression and rs2596191 genotype in metastatic cutaneous melanoma tumor tissue 
in the (g) additive model, (h) dominant model, and (i) recessive model.
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Table 1. Meta-analysis of nine validated SNPs using two published melanoma GWAS datasets 
The MDACC Study (n=858) The Harvard Study (n=409) Meta-analysis 
SNP Allele
1
 Gene Chr EAF HR (95% CI)
 2
 P
2
 FDR
3
 FPRP
3
 EAF HR (95% CI)
 4
 P
4
 Phet I
2
 HR (95% CI)
5
 P
5
 
rs485412 T/C CHRM3 1q43 0.24 0.66 (0.46-0.95) 0.026 0.533 0.200 0.25 0.57 (0.33-0.97) 0.039 0.660 0.000 0.63 (0.47-0.85) 2.90×10
-3
rs1104370 A/G CHRM3 1q43 0.24 0.66 (0.46-0.95) 0.026 0.533 0.200 0.25 0.57 (0.33-0.97) 0.039 0.660 0.000 0.63 (0.47-0.85) 2.90×10
-3
rs2841038 G/T CHRM3 1q43 0.24 0.65 (0.45-0.94) 0.024 0.513 0.187 0.26 0.56 (0.33-0.96) 0.036 0.650 0.000 0.62 (0.46-0.84) 2.10×10
-3
rs2623439
#
A/G PDE1A 2q32.1 0.30 1.44 (1.06-1.95) 0.020 0.479 0.154 0.28 1.51 (1.01-2.28) 0.047 0.860 0.000 1.46 (1.15-1.87) 2.22×10
-3
rs1430157 C/T PDE1A 2q32.1 0.31 1.41 (1.04-1.90) 0.026 0.530 0.188 0.29 1.61 (1.07-2.41) 0.016 0.610 0.000 1.48 (1.16-1.88) 1.52×10
-3
rs6750552 T/C PDE1A 2q32.1 0.33 1.47 (1.08-1.98) 0.013 0.446 0.106 0.30 1.62 (1.07-2.45) 0.021 0.710 0.000 1.52 (1.19-1.94) 7.21×10
-4
rs10931014 T/C PDE1A 2q32.1 0.33 1.39 (1.04-1.87) 0.027 0.535 0.200 0.30 1.65 (1.09-2.49) 0.018 0.510 0.000 1.47 (1.16-1.87) 1.59×10
-3
rs6785564 A/G ITPR1 3p26.1 0.14 0.51 (0.32-0.81) 0.004 0.382 0.062 0.14 0.44 (0.20-0.96) 0.040 0.750 0.000 0.49 (0.33-0.73) 3.94×10
-4
rs2596191 C/A RYR3 15q13.3-q14 0.44 0.69 (0.51-0.93) 0.016 0.460 0.130 0.42 0.64 (0.41-0.98) 0.039 0.780 0.000 0.67 (0.53-0.86) 1.71×10
-3
Abbreviations: SNP: single nucleotide polymorphism; EAF: effect allele frequency; HR: hazards ratio; CI: confidence interval; Phet: P value for heterogeneity by Cochrane’s Q test; GWAS: 
genome-wide association study; MDACC: The University of Texas M.D. Anderson Cancer Center. 
1
 Reference allele/effect allele. 
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2
 Adjusted for age, sex, Breslow thickness, distant/regional metastasis, ulceration and mitotic rate in the MDACC study. 
3.
FDR: false discovery rate; FPRP: false-positive report probability.
4
 Adjusted for age and sex in the Harvard study. 
5
 Meta-analysis in a fix-effects model. 
# 
SNP genotyped, or else SNP imputed.
Table 2. Predictors of CMSS obtained from stepwise Cox regression analysis in the MDACC study 
Parameter
1
 Category
2
 Frequency HR (95% CI) P 
Age ≤50/>50 371/487 1.02 (1.01-1.04) 0.0090 
Sex Female/Male 362/496 1.55 (0.97-2.47) 0.0677 
Regional/distant metastasis No/Yes 709/149 4.52 (2.92-6.99) <.0001 
Breslow thickness(mm) ≤1/>1 347/511 1.16 (1.10-1.22) <.0001 
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Ulceration No/Yes 681/155 2.79 (1.81-4.29) <.0001 
Mitotic rate (mm
2
) ≤1/>1 275/583 2.53 (1.21-5.29) 0.0137 
PDE1A rs6750552 T>C TT/TC/CC 388/376/94 1.48 (1.10-1.99) 0.0104 
ITPR1 rs6785564  A>G AA/AG/GG 636/205/17 0.51 (0.32-0.80) 0.0038 
RYR3 rs2596191 C>A CC/CA/AA 271/411/176 0.69 (0.51-0.93) 0.0166 
Abbreviations: CMSS: cutaneous melanoma-specific survival; MDACC: MD Anderson cancer Center; HR: hazards ratio; CI: confidence interval; 
1 
Stepwise analysis included age, sex, regional/distant metastasis, Breslow thickness, ulceration, mitotic rate and nine SNPs in four genes (rs485412, 
rs1104370, rs2841038 in CHRM3; rs6785564 in ITPR1; rs2596191 in RYR3 and rs2623439, rs1430157, rs6750552, rs10931014 in PDE1A); 
2 
The leftmost was used as the reference. 
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Table 3. Associations between three independent SNPs and CMSS of patients in the MDACC study, the Harvard study and the combined dataset 
The MDACC Study (n=858) The Harvard Study (n=409) MDACC + Harvard (n=1267) 
Genotype All Death (%) HR (95% CI)
1
 P
1
 All Death (%) HR (95% CI)
2
 P
2
 All Death (%) HR (95% CI)
3
 P
3
 
PDE1A rs6750552 T>C 
TT 388 37 (9.54) 1.00 201 15 (7.46) 1.00 589 52 (8.83) 1.00 
TC 376 45 (11.97) 1.56 (0.99-2.46) 0.053 169 28 (16.57) 2.30 (1.23-4.30) 0.010 545 73 (13.39) 1.59 (1.12-2.27) 0.010 
CC 94 12 (13.83) 2.06 (1.08-3.94) 0.029 39 5 (12.82) 2.03 (0.74-5.61) 0.171 133 18 (13.53) 1.74 (1.02-2.98) 0.043 
Trend test 0.013 0.022 0.007 
TC+CC 470 58 (12.34) 1.65 (1.07-2.54) 0.023 208 33 (15.87) 2.25 (1.22-4.15) 0.009 678 91 (13.42) 1.62 (1.15-2.28) 0.006 
ITPR1 rs6785564 A>G 
AA 636 75 (11.79) 1.00 299 41 (13.71) 1.00 935 116 (12.41) 1.00 
AG 205 19 (9.27) 0.58 (0.34-0.99) 0.047 102 7 (6.86) 0.47 (0.21-1.05) 0.067 307 26 (8.47) 0.65 (0.43-1.00) 0.047 
GG 17 1 (5.88) 0.13 (0.02-0.98) 0.048 8 0 (0.0) - - 25 1 (4.00) 0.28 (0.04-1.97) 0.200 
Trend test 0.004 0.040 0.019 
AG+GG 222 20 (9.01) 0.50 (0.29-0.84) 0.009 110 7 (6.36) 0.44 (0.20-0.99) 0.046 332 27 (8.13) 0.62 (0.41-0.94) 0.025 
RYR3 rs2596191 C>A 
CC 271 38 (14.02) 1.00 133 22 (16.54) 1.00 404 60 (14.85) 1.00 
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CA 411 45 (10.95) 0.76 (0.48-1.19) 0.227 205 21 (10.24) 0.64 (0.35-1.16) 0.137 616 66 (10.71) 0.73 (0.51-1.03) 0.071 
AA 176 12 (6.82) 0.44 (0.23-0.87) 0.019 71 5 (7.04) 0.41 (0.15-1.08) 0.070 247 17 (6.88) 0.46 (0.27-0.79) 0.005 
Trend test 0.016 0.039 0.003 
CA+AA 587 57 (9.71) 0.66 (0.43-1.01) 0.054 276 26 (9.42) 0.57 (0.33-1.01) 0.055 863 83 (9.62) 0.65 (0.46-0.90) 0.010 
Number of protective genotypes
4
 
0 108 20 (18.52) 1.00 51 16 (31.37) 1.00 159 36 (22.64) 1.00 
1 367 41 (11.17) 0.58 (0.34-1.00) 0.050 173 18 (10.40) 0.30 (0.15-0.58) 0.0004 540 59 (10.93) 0.44 (0.29-0.67) 0.0001 
2 319 29 (9.09) 0.37 (0.21-0.68) 0.001 141 12 (8.51) 0.24 (0.11-0.51) 0.0002 460 41 (8.91) 0.37 (0.24-0.58) <0.0001 
3 64 5 (7.81) 0.15 (0.05-0.52) 0.003 44 2 (4.55) 0.13 (0.03-0.56) 0.006 108 7 (6.48) 0.23 (0.10-0.52) 0.0004 
Trend test <0.001 0.0002 <0.0001 
0-1 475 61 (12.84) 1.00 224 34 (15.18) 1.00 699 95 (13.59) 1.00 
2-3 383 34 (8.88) 0.49 (0.31-0.76) 0.002 185 14 (7.57) 0.48 (0.26-0.90) 0.021 568 48 (8.45) 0.61 (0.43-0.86) 0.0049 
Abbreviations: SNP: single nucleotide polymorphisms; CMSS: cutaneous melanoma-specific survival; HR: hazards ratio; CI: confidence interval. 
1
 Adjusted for age, sex, Breslow thickness, distant/regional metastasis, ulceration and mitotic rate in Cox models of SNPs and CMSS in the MDACC study. 
2
 Adjusted for age and sex in the Harvard study. 
3.
Adjusted for age and sex in MDACC and Harvard combined dataset; 
4
 Protective genotypes were rs6750552 TT, rs6785564 AG+GG, rs2596191 CA+AA. 
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Figure 1 
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Figure 2 
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Figure 3 
